Besides, it must be taken into account that the possible beneficial effects that have been seen with the activation of the CB2 receptor in these AD models are mainly based on its anti-inflammatory effects related to its expression in the microglia [4, 66], which may indicate that the direction in which the CB2 receptor should be modulated may depend on the type of neurotoxic event to be controlled: activation against inflammatory events in APP-based models and inhibition against neuronal deterioration in TAU-dependent models. The gene discussed is APP; the disease is Alzheimer disease.